| Description |
Publish Date |
LINKS |
Important safety information on vaccines in Moldova
|
10/12/2017 |
|
| Important safety information on Dolutegravir in Moldova |
10/10/2018 |
|
| Important safety information on Abacavir: Hypersensitivity reaction - educational slide deck |
15/02/2024 |
|
| Important safety information on Dolutegravir in Moldova (Safety Notification_Korean label update for Dolutegravir containing products) |
01-11-2023 |
|
| Important safety information on Cephalosporins in Moldova (Safety Notification_Cephalosporins and risk of seizure) |
01/03/2023 |
|
Important safety information on Cephalosporins in Moldova (Safety Notification_Cephalosporins and risk of neurotoxicity) |
07/03/2023 |
|
Important safety information on Amoxicillin / Amoxicillin and clavulanic acid containing products in Moldova |
09/09/2023 |
|
| Important safety information on Lamotrigine containing products in Moldova |
09/09/2023 |
|
| Important safety information on Cefuroxime sodium in Moldova (Safety Notification_Cefuroxime Class 4 Defect MHRA) |
30-10-2023
|
|
| Lamotrigine Safety update for HCP’s in Moldova |
04/12/2023 |
|
| Important safety information on Dolutegravir in Moldova (Safety Notification_Korean label update for Dolutegravir containing products) |
15-11-2023 |
|
Important safety information on Amoxicillin/clavulanic acid containing products - MedSafe communication regarding labelling updates |
18/12/2023 |
|
Important safety information on Paroxetine containing products - Modifications of the information of medicines authorized by national procedure that contain Paroxetine |
25/12/2023 |
|
Important safety information on Amoxycillin/clavulanate containing products - Amendments to the instructions for medical use of medicines containing
amoxicillin/clavulanate, Ukrainian HA website |
29/02/2024 |
|
Important safety information on Lamotrigine containing products - Direct Communication has been received from Risk Management and Drug Information in Israel MOH |
07/03/2024 |
|
Important safety information on Lamotrigine containing products - US FDA direct communication to GSK regarding use of lamotrigine, combined with estradiol products, and the risk of seizures as a potential safety issue |
07/03/2024 |
|
Important safety information on Lamotrigine containing products - Latest Prescriber Update (vol 45:1 March 2024) received from Medsafe |
19/03/2024 |
|
Important safety information on Valaciclovir containing products - Adaptation of the medicinal product information for Valaciclovir containing products |
19/03/2024 |
|
Important safety information on Lamotrigine containing products - Safety Signal received from Swissmedic: Lamictal - Interaction with hormone replacement therapies (HRT) |
04/04/2024 |
|
